Endothelix

What Endothelix does

Endothelix, Inc. is a Houston, Texas-based cardiovascular medical device company founded in 2003 that develops and commercializes the VENDYS II, an FDA-cleared automated office-based device for the non-invasive measurement of vascular reactivity and endothelial function. The company operates as a product line under its parent and technology licensor American Heart Technologies LLC, and targets physicians, cardiologists, and clinical practices that need office-based tools to assess vascular health and stratify cardiovascular event risk in patients.

The VENDYS II is positioned as the only FDA-cleared automated office-based device of its kind, providing clinicians with a direct, non-invasive measurement of vascular function rather than indirect surrogate markers. Endothelix generates revenue through two commercial channels: one-time sales of the VENDYS II device to healthcare institutions and a monthly rental/subscription program that reduces capital barriers for adoption. Pricing is quote-based and not publicly disclosed, with all inquiries routed through a website contact form and direct sales engagement that includes live product demonstrations.

Go-to-market is an enterprise field sales motion targeting healthcare providers, supported by a multi-channel digital presence (LinkedIn, Google Search, YouTube, Twitter/X, Facebook, Instagram, email marketing) and a bottom-of-funnel website demo-scheduling flow. Endothelix maintains an active Knowledge Center featuring peer-reviewed publications on endothelial function, which reinforces clinical credibility and physician education. The company is private, small (1–10 employees), and has only one documented funding round ($500,000 from Houston Angel Network in 2006).

Name

Endothelix

Legal name

American Heart Technologies LLC

Website

https://endothelix.com

Company type

Private

Founded year

2003

Operating status

Operating

Headcount range

1–10 employees

Short description

Endothelix, Inc. is a Houston-based cardiovascular medical device company that commercializes VENDYS II, the only FDA-cleared automated office-based device for non-invasive measurement of vascular reactivity and endothelial function, serving physicians and clinical practices.

Ownership category

akta.pro rank

Product category

Cardiovascular Diagnostic Medical Devices

NAICS

Electromedical and Electrotherapeutic Apparatus Manufacturing (334510)

SIC

Surgical & Medical Instruments & Apparatus (3841)

akta.pro primary industry

Peripheral Vascular Intervention (PAD Stents, Balloons, Atherectomy) (HLAHAFAE)

Keywords

• Cardiovascular diagnostics
• Vascular function testing
• Endothelial function assessment
• Non-invasive medical devices
• Office-based vascular monitoring

Headquarters

HQ city

Houston

HQ country

United States

HQ region

North America

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Supply Chain, Marketing or Sales, Personnel, Operations

Revenue model

1. Medical Device Sales: Sale of VENDYS-II automated endothelial function testing devices to healthcare providers, clinics, and hospitals. The device is an FDA-cleared medical instrument for office-based vascular health assessment.
2. Device Rental: Rental program for VENDYS-II device allowing healthcare providers to access the technology without upfront capital purchase, enabling broader adoption in clinical settings.

Pricing tiers

Go-to-market motion1 record

Distribution channels2 records

Marketing channels9 records

Core offering

Endothelix develops, manufactures, and sells the VENDYS II, an FDA-cleared automated office-based medical device that non-invasively and directly measures vascular reactivity and endothelial function to assess cardiovascular event risk. The device is offered to physicians, cardiologists, and healthcare institutions through direct sales on either a purchase or rental basis, enabling office-based vascular health assessment in clinical settings.

Product overview

Endothelix offers VENDYS II, an FDA-cleared automated medical device for measuring vascular reactivity and endothelial function. The VENDYS II is the current generation product designed for office-based clinical use, providing non-invasive assessment of vascular function and cardiovascular event risk levels. The company also maintains the original VENDYS platform as a prior generation offering.

Differentiator

Problem solved

Functional benefit

Brands

• VENDYS-II: FDA-cleared automated office-based device for measuring vascular reactivity and endothelial function.

Products and services

• VENDYS II FDA-cleared automated office-based medical device that provides a non-invasive and direct assessment of vascular function and cardiovascular event risk levels by measuring vascular reactivity to evaluate endothelial function. Sold or rented to physicians, cardiologists, and healthcare institutions for use in clinical settings.
• VENDYS (Original Platform) Original-generation VENDYS automated office-based device platform for non-invasive endothelial function and vascular health assessment, retained as a prior-generation offering alongside the current VENDYS II device.

Segments2 records

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature1 record

Partnerships

One partnership is on record.

• American Heart Technologies LLCcoreOthersParent company and technology licensor powering the VENDYS II product line. American Heart Technologies LLC is the organization behind the VENDYS endothelial function testing technology, providing the proprietary platform and brand behind the FDA-cleared medical device.

Recent moves5 records

Expansion highlights3 records

Direct peers

• AtCor Medical (SphygmoCor): AtCor Medical (now part of SunTech Medical) developed the SphygmoCor system for non-invasive central blood pressure and arterial stiffness assessment. It is the closest direct peer to Endothelix/VENDYS in office-based non-invasive vascular function measurement.
• USCOM Limited: USCOM produces non-invasive cardiac output and vascular monitoring devices used in clinical and research settings. Comparable to Endothelix as a small-cap, non-invasive cardiovascular hemodynamic measurement device company serving similar clinician end-users.
• Deltex Medical Group: Deltex Medical develops non-invasive and minimally invasive hemodynamic monitoring devices used in perioperative and critical care. Comparable as a small specialist in non-invasive cardiovascular function measurement targeting clinicians and hospitals.

Emerging players

• Itamar Medical (ZOLL Itamar): Itamar Medical (acquired by ZOLL) developed WatchPAT and other non-invasive cardiovascular/sleep diagnostic devices. Comparable as a non-invasive office- or home-based cardiovascular diagnostic company with FDA-cleared products targeting physician use.
• Caretaker Medical: Caretaker Medical develops continuous non-invasive blood pressure and hemodynamic monitoring devices. Comparable as a small specialist in non-invasive vascular monitoring for clinical settings, overlapping with Endothelix's office-based cardiovascular measurement focus.

Broad incumbents

• Philips (Cardiovascular Diagnostics): Philips offers a broad portfolio of cardiovascular diagnostics and monitoring solutions within its connected care and imaging businesses. Overlaps with Endothelix as a vascular/cardiovascular assessment provider but operates at vastly larger scale and across many adjacent categories.
• GE HealthCare: GE HealthCare provides a wide range of cardiovascular diagnostic and monitoring equipment used in hospitals and clinics. Comparable only in the broad sense that both serve cardiovascular assessment needs; Endothelix operates as a specialized niche player versus GE's portfolio scale.
• Omron Healthcare: Omron Healthcare produces vascular health monitors (e.g., blood pressure monitors, arterial stiffness indicators) for both clinical and consumer use. Comparable as an adjacent vascular-function measurement device vendor, though it does not target the same endothelial function testing niche.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat3 records

Key risks5 records

Key highlights5 records

Customer concentration

• Xtwitter.com/VENDYS_2
• YouTubeyoutube.com/watch?v=d2oJsBzirrs&t=1s
• LinkedInlinkedin.com/company/endothelix

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Endothelix